Stocks / Stock overview
Iovance Biotherapeutics, Inc. (IOVA)
Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.
Aft $7.72 (-0.52%)
NasdaqGM · Price as of · Nasdaq Real Time Price
Stock Scorer
Scoring…
Analyst consensus
$14.50
- Analysts10
- Implied upside+86.9%
- Target range$8.00 to $20.00
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | November 13, 2026 | OWNERSHIP DOCUMENT |
| 4 | November 12, 2026 | OWNERSHIP DOCUMENT |
| 4 | November 10, 2026 | OWNERSHIP DOCUMENT |
| SCHEDULE 13G | November 10, 2026 | View on EDGAR |
| 8-K | November 5, 2026 | 8-K |
| 10-Q | November 5, 2026 | 10-Q |
| 8-K | November 5, 2026 | FORM 8-K |
| 8-K | October 29, 2026 | FORM 8-K |
Articles that mention Iovance Biotherapeutics without it being the main subject.
Frequently asked questions
What do analysts expect for IOVA?
10 analysts cover Iovance Biotherapeutics, Inc. (IOVA). The consensus rating is Buy. The average price target is $14.50, in a range of $8.00 to $20.00.
Are insiders buying or selling IOVA?
We have no qualifying Form 4 insider purchases or sales on record for Iovance Biotherapeutics, Inc. (IOVA). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see IOVA SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed November 13, 2026.
Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.